Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Laibin People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05994339
A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer
Completed
- Conditions
- The Primary Study Metric is Progression-free Survival (PFS)
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Laibin People's Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT05934461
News
No news found